COMMUNIQUÉS West-GlobeNewswire

-
OSE Immunotherapeutics provides an update on ongoing proceedings
25/06/2025 -
Essential Pharma strengthens Board with the appointment of Nicola Heffron as Non-Executive Director
25/06/2025 -
Actimed Therapeutics Enrolls First Patients in Phase 2a PROACT Study Programme to Assess S-pindolol benzoate in Obese Patients During and Post-GLP-1 Agonist Therapy
25/06/2025 -
Nipocalimab showed greater sustained disease control versus approved FcRn blockers for generalised myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC)
25/06/2025 -
Aja Health and Wellness Inc. Provides Update on Delay in Filing Financial Statements
25/06/2025 -
Cidara Announces Pricing of Upsized Public Offering of Common Stock
25/06/2025 -
Une première autorisation de distribution de la fleur de cannabis médicinal à des fins thérapeutiques délivrée par le ministère de la Santé italien pour Tilray Medical
25/06/2025 -
Shiny Smile Veneers Named Top Snap-On Veneer Brand in the US by Independent Review Platforms
24/06/2025 -
Abvance Therapeutics Secures Strategic Seed Financing & Leadership Expansion at ADA Scientific Sessions
24/06/2025 -
Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia
24/06/2025 -
Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium
24/06/2025 -
InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke
24/06/2025 -
BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® Congress
24/06/2025 -
NeuroPace Announces Strategic CFO Transition
24/06/2025 -
Administrative Law Judge Determines ReWalk Personal Exoskeleton is “Reasonable and Necessary” for Medicare Beneficiary
24/06/2025 -
Shuttle Pharmaceuticals Announces Closing of $4.25 Million Private Placement Priced At-the-Market
24/06/2025 -
TerrAscend Announces Results of Annual General Meeting
24/06/2025 -
Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company’s Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease
24/06/2025 -
Glass House Brands Inc. Announces Voting Results Following Annual and Special Meeting
24/06/2025
Pages